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Abstract
Background: Although Tim-3 & PD-L1 signaling pathways play important roles in negatively regulating immune
responses, their roles in chlamydial infection have not been evaluated.
Methods: Neutralization antibodies targeting Tim-3 and PD-L1 were used to treat mice. Following an intravaginal
infection with C. muridarum organisms, mice with or without the dual antibody treatment were compared for live
chlamydial organism shedding from the lower genital tract and inflammatory pathology in the upper genital tract.
Results: Mice treated with anti-Tim-3 and anti-PD-L1 antibodies displayed a time course of live organism shedding
similar to that of mice treated with equivalent amounts of isotype-matched IgG molecules. The combined antibody
blocking failed to alter either the lower genital tract cytokine or systemic humoral and cellular adaptive responses
to C. muridarum infection. However, the antibody blocking significantly enhanced C. muridarum-induced
pathologies in the upper genital tract, including more significant hydrosalpinx and inflammatory infiltration in
uterine horn and oviduct tissues.
Conclusions: The Tim-3 and PD-L1-mediated signaling can significantly reduce pathologies in the upper genital
tract without suppressing immunity against chlamydial infection, suggesting that Tim-3 and PD-L1-mediated
negative regulation may be manipulated to attenuate tubal pathologies in women persistently infected with C.
trachomatis organisms.
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Background
Chlamydia trachomatis causes the most frequent sexually
transmitted bacterial infections [1-3], which, if untreated,
can lead to complications characterized with tubal inflam-
matory damages, including pelvic inflammatory diseases,
ectopic pregnancy and infertility [1,4,5]. Although both
intracellular replication of C. trachomatis organisms and
host responses to C. trachomatis antigens may signifi-
cantly contribute to inflammatory pathologies [6-9], the
precise pathogenic mechanisms of C. trachomatis-induced
diseases remain unknown. In addition, there is still no
licensed C. trachomatis vaccine [10] despite the urgent
need and extensive efforts in searching for such a vaccine.
Previous immunological studies, mainly based on a
C. muridarum intravaginal infection mouse model, have
revealed that a Th1-dominant cell-mediated immunity is
required for protection against Chlamydia urogenital
tract infection [10-12]. It is also hypothesized that exces-
sive and/or prolonged cellular (particularly CD + 8 T
cell) responses may contribute to tubal pathologies dur-
ing chlamydial infection [13,14]. However, how these
protective and pathogenic cellular responses are regu-
lated remains unknown. Both Tim-3 (T cell immunoglo-
bulin and mucin domain 3) and PD-1 (Programmed
death one) are negative regulators of T cell responses
* Correspondence: Zhongg@UTHSCSA.edu
1Department of Microbiology and Immunology, University of Texas Health
Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX
78229, USA
Full list of author information is available at the end of the article
Peng et al. BMC Infectious Diseases 2011, 11:347
http://www.biomedcentral.com/1471-2334/11/347
© 2011 Peng et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
[15,16]. We evaluated the role of these two negative reg-
ulatory signaling pathways in chlamydial urogenital
infection in the current study.
Tim-3-mediated signal inhibits both CD4+ Th1 and
CD8+ T cell responses, which may prevent unintended tis-
sue inflammation [17]. However, inappropriate activation
of Tim-3 signals may lead to premature T cell exhaustion,
thus, permitting persistent or chronic infection [18-21].
Tim-3 has emerged as a promising therapeutic target to
correct abnormal immune function in several autoimmune
and chronic inflammatory conditions [22]. PD-1 is an
inducible molecule on activated T and B lymphocytes and
plays a critical role in controlling lymphocyte activation
and maintaining peripheral tolerance [19,23]. PD-L1, the
primary regulatory counter-receptor for PD-1 in the per-
ipheral tissues is broadly inducible in various tissues and
cell types [23-26]. The interaction between PD-1 and PD-
L1 plays a critical role in determining the fate of T-cell
activation and tolerance during T-cell priming [23]. Like
Tim-3, inappropriate activation of PD-1 signaling can lead
to immune suppression and persistent/chronic infection
[27]. For example, PD-1-PD-L1 pathway has been shown
to impair Th1 immune response in the late stage of infec-
tion with Mycobacterium bovis bacillus Calmette-Guérin,
thereby facilitating the bacterial persistence in the host
[28]. Decrease in the exhaustion markers PD-1 and TIM-3
in T cells correlates with reduction of Mycobacterium
tuberculosis load in the lungs [29]. Thus, blocking PD-1
signaling pathway may prevent persistent infection.
However, Targeting the PD-1-PD-L1 pathway alone does
not always result in complete restoration of T cell function
[30]. Double blocking with neutralization antibodies
against both Tim-3 and PD-L1 has been shown to restore
T cell function in both solid tumor-bearing mice [31] and
mice chronically infected with viruses [32], leading to con-
trolling tumor growth and viral infection respectively.
Thus, in the current study, we used a combined blocking
approach to assess the effect of Tim-3 and PD-L1 signaling
pathways on Chlamydia infection in a C. muridarum intra-
vaginal infection mouse model. We found that the C. muri-
darum organism shedding time course after an intravaginal
infection was not altered despite the double blocking.
However, the tubal pathology following the C. muridarum
infection was more severe in mice treated with neutraliza-
tion antibodies targeting both Tim-3 and PD-L1. These
observations suggest that Tim-3 and PD-L1 signaling may
play an important role in reducing pathologies in the
upper genital tract after chlamydial infection.
Materials and methods
Mouse infection, antibody treatment and titration of live
organism shedding
C. muridarum Nigg strain (also called MoPn) organisms
used in the current study were grown in HeLa cells
(ATCC, Manassas, VA 20108), purified and titrated as
described previously [9]. Female Balb/c mice were pur-
chased at the age of 6 to 8 weeks old from Charles River
Laboratories, Inc. (Wilmington, MA). Each mouse was
inoculated intravaginally with 2 × 104 IFUs of live
C. muridarum organisms as described previously [9].
After infection, the mice were treated with either neutrali-
zation antibodies or isotype control IgG for 12 days as fol-
lowing: For the anti-Tim-3 + PD-L1 group, each mouse
was injected intraperitoneally (i.p.) with 100 μg of anti-
Tim-3 (clone# 8B.2 C12; Rat IgG1, cat#16-5871,
eBioscience, San Diego, CA) on days 0 (the same day of
infection), 2 and 4, 200 μg of anti-PD-L1 (clone 10 F.9 G2,
Rat IgG2b, cat#124309, Biolegend, San Diego, CA) on
days 0, 3, 6, 9 and 12. For the control group, each mouse
was similarly injected with the equivalent amounts of iso-
type-matched rat IgGs following the same injection sche-
dule. After the intravaginal infection, vaginal swabs were
taken once every 7 days until two consecutive negative
detection results were obtained from the same mouse.
The chlamydial organisms released from swabs were
inoculated onto HeLa cell monolayers in duplicates as
described previously [8]. An immunofluorescence assay
was used to quantitate live organisms (expressed as inclu-
sion forming units or IFUs) from each swab as described
previously [9]. The number of IFUs/swab was converted
into log10 and the log10 IFUs were used to calculate means
and standard deviation for each group at each time point.
Evaluating mouse genital tract tissue pathologies and
histological scoring
Mice were sacrificed 60 days after infection and the mouse
urogenital tract tissues were isolated. Before the tissues
were removed from mice, an in situ gross examination
was performed for evidence of hydrosalpinx formation
and any other abnormalities. The excised tissues were pro-
cessed for making serial sections. Efforts were made to
include cervix, both uterine horns and oviducts as well as
lumenal structures of each tissue in each section. The sec-
tions were stained with hematoxylin and eosin (H&E) and
assessed by a board certified pathologist (I-T.Y) blinded to
mouse treatment for severity of inflammation and pathol-
ogies based on the modified schemes established pre-
viously [8]. The uterine horns and oviducts were scored
separately. Scoring for dilatation of uterine horn or fallo-
pian tube: 0, no significant dilatation; 1, mild dilatation of
a single cross section; 2, one to three dilated cross sections;
3, more than three dilated cross sections; and 4, confluent
pronounced dilation. Scoring for inflammatory cell infil-
trates (at the chronic stage of infection, the infiltrates
mainly contain mononuclear cells): 0, no significant infil-
tration; 1, infiltration at a single focus; 2, infiltration at two
to four foci; 3, infiltration at more than four foci; and 4,
confluent infiltration. Scores assigned to individual mice
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were calculated into means ± standard errors for each
group of animals.
Immunofluorescence assay
For titrating IFUs from mouse swab samples, HeLa cells
grown on glass coverslips in 24 well plates were inocu-
lated with serially diluted swab samples and processed
for immunofluorescence assay 24 h after infection. The
cell samples were labeled with Hoechst (blue, Sigma) for
visualizing DNA and a rabbit anti-chlamydial chaperon
cofactor antibody (unpublished data) plus a goat anti-
rabbit IgG conjugated with Cy2 (green; Jackson Immu-
noResearch Laboratories, Inc., West Grove, PA) for
visualizing chlamydial inclusions. The immuno-labeled
cell samples were quantitated and used for image analysis
and acquisition as described previously [33,34]. For titrat-
ing anti-C. muridarum antibodies in mouse serum sam-
ples, the C. muridarum-infected HeLa cells were
processed and added with serially diluted mouse serum
samples. After the primary antibody binding, a goat anti-
mouse IgG conjugated with Cy3 (red; Jackson ImmunoR-
esearch Laboratories) was used to visualize the mouse
antibody binding to C. muridarum organisms. The anti-
body titer was defined as the highest dilution that still
showed positive fluorescence labeling and expressed as
log10 dilutions for statistic analyses.
Enzyme-Linked Immunosorbent Assay (ELISA)
Cytokines from mouse vaginal swabs and mouse spleno-
cyte culture supernatants (after in vitro restimulation)
were measured using Bio-plex Pro™ mouse cytokine stan-
dard Group I 23-plex (cat# 171I5001, BIO-RAD, Hercules,
CA) and Group II 9-plex (cat# 171I6001) kits by following
the manufacturer’s instruction. Since all 32 cytokine beads
are uniquely labeled, they were mixed and used in the
same assays. For swab samples, after the C. muridarum
organism titration, each of the left over swab samples was
diluted 1:2 in PBS containing 10% fetal bovine serum.
50 ul of the diluted sample was added to each reaction
well containing the 32 cytokine beads (each type of beads
is covalently coated with a capture antibody specifically
recognizing one cytokine). To prepare the splenocyte sam-
ples, splenocytes were harvested from mice 60 days after
C. muridarum infection and stimulated in vitro with UV-
inactivated C. muridarum organisms (elementary bodies
or EBs) or medium alone for 3 days. The culture superna-
tants were diluted 1:2 and 50 ul were used to react with
the 32 cytokine beads. The bead capture antibody-bound
cytokines were detected with biotinylated detection anti-
bodies and phycoerythrin fluorescence-conjugated Avidin.
The fluorescence-associated with each cytokine was quan-
titated using a Bio-Plex Luminex system (BIO-RAD). The
concentrations of each cytokine were determined based
on the standards measured in the same plate and sample
dilution factors using Bio-Plex Manager software (BIO-
RAD) and expressed as pg/ml. The 32 cytokines analyzed
were: IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10,
IL-12 (p40), IL-12 (p70), IL-13, IL-17, Eotaxin, G-CSF,
CM-CSF, IFN-g, KC, MCP-1, MIP-1a, MIP-1b, RANTES,
and TNFa, IL-15, IL-18, Basic FGF, LIF, M-CSF, MIG,
MIP-2, PDGF-BB and VEGF.
Statistical analysis
ANOVA Test (http://www.physics.csbsju.edu/stats/
anova.html) was performed to analyze the IFU, cytokine
& antibody titration data from multiple groups and a
two-tailed Student t test (Microsoft Excel) to compare
two given groups. For qualitative data analyses, the Chi-
square or Fisher’s Exact tests were used.
Results
Blockade of Tim-3 and PD-L1 signaling pathways did not
alter live organism shedding following an intravaginal
infection with Chlamydia muridarum
Mice treated with a combination of neutralization antibo-
dies against Tim-3 and PD-L1 or isotype-matched control
IgG were compared for live organism shedding following
an intravaginal infection (Figure 1). A schedule of antibody
treatment for 12 days after infection was used (panel A)
based on previous studies showing that such a treatment
schedule is most effective in inhibiting Tim-3 and PD-L1
signaling in other disease models [31,32]. However, even
the double blocking of Tim-3 and PD-L1 signaling did not
affect the time course of vaginal shedding of infectious
organisms (panels B & C). All mice shed more than 100
thousand live organisms during the first 2 weeks after C.
muridarum infection. By day 21, 80% mice from both
groups each released about 100 live organisms. By day 28,
most mice cleared infection. These observations suggest
that inhibition of Tim-3 and PD-L1 signaling during the
first 2 weeks post infection did not significantly affect host
immunity against C. muridarum intravaginal infection.
Inhibition of Tim-3 and PD-L1 signaling pathways
significantly enhanced upper genital tract pathologies
When the gross pathology of urogenital tract tissues har-
vested 60 days after infection was compared between the
two groups of mice (Figure 2 & Table 1), we found that 8
of the 10 mice from the isotype control group and all 10
mice from the antibody treatment group developed
hydrosalpinx although the severity of hydrosalpinx varies
a great deal among different oviducts. We developed a
scoring system for semi-quantitatively assessing the
severity of hydrosalpinx in each oviduct over the years
[8]. A total of 14 out of the 20 oviducts from the 10 anti-
body-treated mice received the highest hydrosalpinx
severity score 4 while only 7 oviducts from the isotype
control group received the same score (p < 0.05). This
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observation suggests that blocking Tim-3 & PD-L1 sig-
naling pathways may promote the inflammatory
responses in the oviduct and enhance the progression of
hydrosalpinx. When H&E-stained mouse urogenital tis-
sues were examined under a microscope, inflammatory
infiltrates were significantly higher in oviduct tissues of
mice treated with anti-Tim-3 & PD-L1 antibodies (Figure
3). The neutralization antibody-treated mice also dis-
played more severe oviduct luminal dilatation. Thus,
blocking Tim-3 and PD-L1 signaling pathways can lead
to exacerbation of tubal inflammatory pathologies.
The effect of Tim-3 and PD-L1 blockade on genital tract
cytokine responses and adaptive immunity to C.
muridarum infection
To understand the immunological basis of the Tim-3 &
PD-L1 blockade-enhanced tubal inflammation, we moni-
tored the cytokine production in the mouse vaginal
Figure 1 Effect of targeting the Tim-3 and PD-1 signaling pathways on live organism shedding following chlamydial infection. (A) All
mice were intravaginally infected with live C. muridarum organisms and vaginal swabs were taken along the infection course as indicated along
the horizontal line for monitoring the shedding of live organisms. One group of mice were treated with anti-Tim-3 plus anti-PD-L1 neutralization
antibodies while the other group with isotype-matched rat IgGs as indicated. (B) The number of live organisms recovered from each swab was
expressed as IFUs. After converting into Log10, and the log10 IFUs were used to calculate mean and SD for each mouse group as displayed
along the y-axis and at a given time point along the infection course (X-axis). The log10 IFUs along the time course were analyzed with ANOVA,
and no significant differences at any time points were found between the control and Tim-3 + PD-L1 groups. (C) Number of mice still positively
shedding live chlamydial organisms (IFU+) versus the total of mice (total) in each group (antibody treatment group, aTim-3 & aPD-L1 or isotype
control group) were listed as function of infection time (horizontally).
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Figure 2 Effect of targeting the Tim-3 and PD-1 signaling pathways on the development of urogenital tract gross pathology. Groups
of control and anti-Tim-3 + PD-L1 treatment mice were infected with C. muridarum as described in Figure1 legend. Sixty days after infection,
mice were sacrificed for harvesting genital tissues and the pathology of the mouse genital tissues was evaluated under both naked eyes for
gross appearance. The left column in each group (a-j from control and k to t from antibody treatment group) displayed the overall appearance
of the entire upper genital tract (UGT), whereas the right two narrow columns were amplified images of the oviduct/ovary portion from both
left (for example, marked with a1) and right (a2) sides. Swollen oviducts from either side were marked according to the severity as followings:
No hydrosalpinx is assigned a score of zero (0); Hydrosalpinx is only visible after amplification (1); Hydrosalpinx is clearly visible with naked eye
but the size is smaller than that of ovary (2); The size of hydrosalpinx is similar to that of ovary (3) or larger than ovary (4). * indicates a swollen
oviduct with a severity score of 4 (panel g1) but the bubble was accidentally broken during isolation. The incidence and severity of hydrosalpinx
were summarized in Table 1.
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Table 1 Incidence of gross pathologies
Group Total mice No of mice Total oviducts No of oviducts with hydrosalpinx scores
None Uni Bi 0 1 2 3 4 Total score
Isotype control 10 2 0 8 20 4 2 2 5 7* 49
aTim-3+ aPD-L1 10 0 1 9 20 1 2 0 3 14* 67
*p = 0.028
Mice were sacrificed 60 days after infection and the reproductive tissues were isolated and inspected for gross pathologies (see Figure 2 for images). Number of
mice without (none) or with hydrosalpinx on single (Uni) or both (Bi) sides of the reproductive tissues was listed on the left portion of the table. Number of
oviducts without (0) or with varying severity degrees (1 to 4) of hydrosalpinx was listed on the right portion of the table. Fisher Exact test was used to compare
the differences in incidences of mouse with hydrosalpinx or oviducts with varying degrees of hydrosalpinx between the control and antibody treatment groups.
P-vales with statistic differences were marked. * stands for p < 0.05.
Figure 3 Effect of targeting the Tim-3 and PD-L1 signaling pathways on upper genital tract inflammatory pathology examined
microscopically. (A) After the gross appearance observation, the same tissues were subjected to histological section analyses under microscope
(after H&E staining). Representative H&E stained section images covering either uterine horn (panels a, c, e & g) or oviduct (b, d, f & h) regions
were presented from each group (a-d from control group while e to h from anti-Tim-3 + PD-L1 treatment group). Each section was scored for
both lumenal dilatation (DI, panels a, b, e & f) and inflammatory infiltration (IN, panels c, d g & h). Lumenal dilation was marked with a white line
with arrowheads at both ends and while infiltrates marked with white arrows. The semi-quantitation results were presented in (B). Dilation (left
plot) and inflammation (right plot) scores (derived from 5 different sections) assigned to individual mice were used to calculate the means and
standard errors for each group as shown along the Y-axis. The mouse and tissue groups were indicated either inside the plots (open bar for
control while solid bar for antibody treatment groups) or along the X-axis. The scores were compared between different groups using ANOVA
followed by the two-tailed Student t test. The p values with statistic significance were indicated accordingly.
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swab samples using the Bio-Rad Bio-Plex cytokine kits
(data not shown). A total of 32 cytokines were measured
in swab samples harvested on day 3, 7 & 14 after C.
muridarum infection. There were no significant differ-
ences in any of the cytokines measured between the
antibody treatment and control groups (data not
shown). We further monitored the adaptive immunity
by measuring C. muridarum-specific humoral (Figure
4A) and T cell responses (Figure 4B). Both groups of
mice produced robust antibody responses and there was
no significant difference in antibody titers between the
two groups. More importantly, the two groups of mice
also displayed similar phenotypes of C. muridarum-spe-
cific T cell responses and there was no significant differ-
ence in the amounts of IL-5 (by Th2 cells), IL-17
(Th17) or IFNg (Th1-like) produced in the supernatants
of C. muridarum-restimulated splenocytes harvested
from the two groups of mice.
Discussion
Using a combined blocking of Tim-3 and PD-L1, we
assessed the role of Tim-3 and PD-L1 signaling path-
ways in chlamydial infection. Despite the double block-
ade, the time course of live organism shedding from the
lower genital tract after C. muridarum infection was not
significantly altered. Since the double blocking with neu-
tralization antibodies targeting both Tim-3 and PD-L1
has been shown to effectively suppress both Tim-3 and
PD-L1 signaling pathways [31,32], the above result sug-
gests that Tim-3- and PD-1-meditaed negative regula-
tion signaling pathways might not significantly suppress
host immunity against chlamydial infection in lower
Figure 4 Effect of targeting the Tim-3 and PD-1 signaling pathways on C. muridarum-specific humoral and cellular responses. (A)
Serum IgG antibodies from both groups (open squares for control and filled squares for anti-Tim-3 + PD-L1 treatment) were titrated using C.
muridarum-infected HeLa cells as antigens under an immunofluorescence assay. The Log10 dilution was used to calculate the mean and
standard deviation from each group as displayed along the Y-axis and at a given time along the infection time course (X-axis). There was no
statistic difference in antibody titers between the two groups at any time points (ANOVA). (B) A total of 32 mouse cytokines were measured
(using the Bio-Rad Bio-Plex kits) from the supernatants of splenocytes harvested from either control or antibody-treated groups were in vitro
restimulated with medium alone (open bar) or UV-inactivated C. muridarum EBs (solid bar) as indicated along the X-axis. The cytokine
concentrations from each group and restimulation condition were calculated in pg or ng/ml as mean and standard deviation as displayed along
the Y-axis. Only the cytokines representing Th2 (IL-5, panel a), Th17 (IL-17, b) and Th1 (IFNg, c) were shown and the other 29 cytokines were not
shown. There was no statistic difference in any of the 32 cytokine concentrations between the two groups.
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genital tract. This conclusion is consistent with the
observations that treatment with anti-Tim3 and PD-L1
neutralizing antibodies did not alter either the lower
genital tract local cytokine production or the systemic
humoral or cellular responses to C. muridarum infec-
tion. The fact that the antibody treatment did not affect
the balance of Th1 versus Th2 responses may explain
the failure of the antibody blocking to impact the lower
genital tract infection time course. However, the treat-
ment of mice with anti-Tim-3 and anti-PD-1 neutraliza-
tion antibodies did significantly enhance pathologies in
the upper genital tract, demonstrating that the antibody
treatment was effective in blocking of Tim-3 and PD-L1
signaling pathways. More importantly, this observation
suggests that Tim-3- and PD-L1-mediated negative reg-
ulation signaling pathways may play significant roles in
reducing pathogenic responses induced by chlamydial
infection in the upper genital tract. Apparently, this
negative regulation didn’t make the lower genital tract
more susceptible to chlamydial infection since removal
of the negative regulation did not reduce live chlamydial
organism shedding.
Given the multifaceted roles of Tim-3 and PD-L1
signaling pathways, it is unexpected that double block-
ing of these two pathways did not alter C. muridarum
infection time course in the lower genital tract. The
combined blocking of Tim-3 and PD-L1 has been
shown to fully restore the functionality of exhausted T
cells expressing both Tim-3 and PD-1 in tumor-bear-
ing animals and chronically infected hosts with viruses
[31,32]. Under these chronic pathogenic conditions,
the negative regulatory roles of Tim-3 and PD-1 may
be heightened or exacerbated. The impact of inhibition
of the exacerbated negative regulation can be more
sensitively detected immunologically and clinically.
However, intravaginal infection with C. muridarum is
an acute infection. The role of Tim-3 and PD-1 in
acute infection is not as well understood as in chronic
infection. A recent study has shown that Th1 immune
responses at the lower genital tract are regulated by
IL-10-producing dendritic cells [35], which may be
independent of Tim-3- or PD-1-mediated mechanisms.
In addition, it has been demonstrated that interaction
of Tim-3 on T cells with its ligand Galectin9 (Gal9) on
macrophages may promote clearance of intracellular
Mycobacterium tuberculosis [36]. Tim3-Gal9 interac-
tion leads to macrophage activation and stimulates
bactericidal activity by inducing caspase-1-dependent
IL-1b secretion [36]. Thus, Tim-3 may also play a
positive role in controlling chlamydial infection. Block-
ing Tim-3 signaling with neutralizing antibodies
remove both the negative and positive roles of Tim-3
in chlamydial infection, resulting in null net effect on
the live organism shedding time course. However,
since the double antibody blocking treatment affected
neither the lower genital tract local cytokine nor the
systemic adaptive immune responses to C. muridarum
infection, it is more likely that the negative regulation
mediated by Tim-3 and PD-L1 did not significantly
inhibit host immunity during the acute phase of C.
muridarum in the lower tract.
The double antibody treatment significantly enhanced
tubal inflammatory pathology, which is consistent with
the overall concept that the negative regulation
mediated by Tim-3 and PD-L1 plays an important role
in minimizing inflammatory damages caused by exces-
sive and prolonged immune responses [26,37]. What is
the cellular basis of the tubal pathology-exacerbating
responses negatively regulated by Tim-3 and PD-L1?
Although Tim-3 and PD-1 can negatively regulate both
CD4+ Th1 and CD8+ T cells, under various chronic
infection or tumor-bearing conditions, the frequency of
antigen-specific CD8+ T cells positive for both TIM-3
and PD-1 is the highest [16,19,21]. Double blocking
with neutralization antibodies to Tim-3 and PD-1 could
fully restore the functionality of the exhausted CD8+ T
cells. Thus, it is assumed that the enhanced anti-tumor
or anti-viral effects restored by the anti-Tim-3 and PD-1
antibodies were due to the removal of negative regula-
tion from CD8+ T cells. Although the cellular basis of
inflammatory responses involved in tubal pathology
after chlamydial infection is still not clear, some pre-
vious studies have correlated CD8+ responses with
pathogenic responses in the upper genital tract [13].
Indeed, mice deficient in MHC class I or CD8 displayed
normal infection time courses in the lower genital tract
[12,38] but developed less severe pathology in the upper
genital tract. TNFa produced by CD8+ T cells may con-
tribute to the tubal pathologies [13]. It is possible that
Tim-3 and PD-L1 may mainly target antigen-specific
CD8+ T cells during chlamydial infection as observed
during mycobacterial infection [28].
Conclusions
Dual blockade of Tim-3 and PD-L1-mediated signaling
pathways significantly reduced inflammatory pathologies
in the upper genital tract but without affecting immu-
nity in the lower genital tract against chlamydial infec-
tion suggests that Tim-3 and PD-L1-mediated negative
regulation may be manipulated to attenuate tubal
pathologies in women persistently infected with C. tra-
chomatis organisms.
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